标题 |
A multicenter, open-label, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in non-small cell lung cancer patients receiving docetaxel/ramucirumab chemotherapy
聚乙二醇格司汀降低接受多西他赛/ramucirumab化疗的非小细胞肺癌患者发热性中性粒细胞减少风险的多中心、开放、随机试验
|
网址 | |
DOI |
暂未提供,该求助的时间将会延长,查看原因?
|
其它 | 发表时间2016,作者UMIN,摘要:INTERVENTION: pegfilgrastim non‐use group(daily use of G‐CSF is permitted at the time of grade 4 neutropenia or febrile neutropenia) pegfilgrastim use group CONDITION: Non‐small cell lung cancer PRIMARY OUTCOME: incidence of febrile neutropenia during the first cycle of treatment SECONDARY OUTCOME: Lowest white blood cell count, Lowest neutrophilic count, Days to febrile neutropenia, Days to a neutropenia to recovery, Adverse events, Severe adverse events, Association with the previously treated regimen INCLUSION CRITERIA: 1)Histologically or cytologically proved non‐small cell lung cancer 2)Relapse or a case considered no surgical indication 3)ECOG Performance Status 0‐2 4)Scheduled to be the combination therapy of docetaxel and ramucirumab |
求助人 | |
下载 |